<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=US-ASCII">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rafal@smigrodzki.org)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-13">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Fri Feb 14 08:09:46 2003" -->
<!-- isoreceived="20030214150946" -->
<!-- sent="Thu, 13 Feb 2003 15:56:53 -0500" -->
<!-- isosent="20030213205653" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rafal@smigrodzki.org" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLCEOBCJAA.rafal@smigrodzki.org" -->
<!-- charset="US-ASCII" -->
<!-- inreplyto="013e01c2d07e$9fa51c90$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rafal@smigrodzki.org?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rafal@smigrodzki.org</em></a>)<br>
<strong>Date:</strong> Thu Feb 13 2003 - 13:56:53 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2700.html">Rafal Smigrodzki: "RE: right to drive cars"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2698.html">Amara Graps: "Re: Media Bias"</a>
<li><strong>In reply to:</strong> <a href="2399.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2760.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2760.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2699">[ date ]</a>
<a href="index.html#2699">[ thread ]</a>
<a href="subject.html#2699">[ subject ]</a>
<a href="author.html#2699">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<p><em>&gt; Because this discussion list is not a support list for Parkinson's
</em><br>
<em>&gt; Disease patients, I suggest we stop focusing only on PD and start
</em><br>
<em>&gt; focusing on the likely risks/benefits of selegiline in healthy and
</em><br>
<em>&gt; aging people.
</em><br>
<p>### I am not aware of any class I or class II evidence for life extension in
<br>
healthy, non-PD humans. Animal studies and uncontrolled trials can be
<br>
intriguing and even entertaining, but I personally would not spend my money
<br>
on anything that has only class IV or animal research data going for it.
<br>
There are other options, like Aggrenox (shown by class I evidence to reduce
<br>
stroke by almost 30% in susceptible populations), the statins that I already
<br>
mentioned, and ACE inhibitors, shown in the HOPE and other trials to reduce
<br>
stroke, and myocardial infarction.
<br>
<p>Of course, I do support to the right of every customer to interpret the
<br>
available data as he or she wishes, and I do not get upset if their
<br>
conclusions, which they support with their own money, are different than
<br>
mine. However, I always insist on the balanced portrayal of the validity of
<br>
in vitro data, animal studies, uncontrolled human and finally, controlled
<br>
human studies with directly important endpoints (e.g. 5-year survival,
<br>
stroke and disability, as opposed to secondary indicators, such as blood
<br>
pressure, or occurrence of PVC's).
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2700.html">Rafal Smigrodzki: "RE: right to drive cars"</a>
<li><strong>Previous message:</strong> <a href="2698.html">Amara Graps: "Re: Media Bias"</a>
<li><strong>In reply to:</strong> <a href="2399.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2760.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2760.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2699">[ date ]</a>
<a href="index.html#2699">[ thread ]</a>
<a href="subject.html#2699">[ subject ]</a>
<a href="author.html#2699">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Fri Feb 14 2003 - 08:12:21 MST
</em></small></p>
</body>
</html>
